Cryptophycin 52 and cryptophycin 55 in sequential and simultaneous combination treatment regimens in human tumor xenografts

In Vivo

Volumn 14, Issue 4, 2000, Pages 471-480

  Teicher, B A ^a   Forler, P ^a   Menon, K ^a   Phares, V ^a   Amsrud, T ^a   Shih, C ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Combination treatment regimens; Cryptophycin 52; Cryptophycins; Radiation sensitizers

Indexed keywords

CARBOPLATIN; CRYPTOPHYCIN 52; CRYPTOPHYCIN DERIVATIVE; DOCETAXEL; FLUOROURACIL; GEMCITABINE; IRINOTECAN; PACLITAXEL;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLON CARCINOMA; CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; OVARY CARCINOMA; TUMOR CELL LINE; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 0033861796     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Pharmaceuticals from cultured algae
2. Preclinical anticancer activity of cryptophycin-8
3. Mechanism of action of the unusually potent microtubule inhibitor, cryptophycin 1
4. Preclinical antitumor activity of cryptophycin-52/55 (C-52;C-55) against human tumors in SCID mice
5. LY355702 and LY355703, new cryptophycin analogues with antitumor activity against human tumor xenografts
6. Antitumor activity of cryptophycins: Effect of infusion time and combination studies
7. Total structures of cryptophycins, potent antitumor desipeptides from the blue-green algae Nostoc sp. Strain GSV
8. Microtubules
9. Mechanism of action of cryptophycin
10. Cryptophycin: A new microtubule agent active against drug-resistant cells
11. Pharmacological probes of microtubule function
12. Microtubule dynamics: Taking aim at a moving target
13. Cryptophycin-induced hyperphosphorylation of bcl-2, cell cycle arrest and growth inhibition in human H460 NSCLC cells
14. Antimitotic natural products and their interactions with tubulin
15. Characterization of the interaction of cryptophycin 1 with tubulin: Binding in the vinca domain, competitive - inhibition of dolastatin 10 binding, and an unusual aggregation reaction
16. Interaction of cryptophycin 1 with tubulin and microtubules
17. Induction of apoptosis by cryptophycin 1, a new antimicrotubule agent
18. Cryptophycin 1 binds to tubulin at a site distinct from the colchicine binding site and at a site that may overlap the vinca binding site
19. Phase I trial of the cryptophycin analogue LY355703 administered as an IV infusion, D1 and D8, repeated every 21 days
20. Binding of the epoxide cryptophycin analog, LY355703 to albumin and its effects on in vitro antiproliferative activity
21. In vitro pharmacology of LY355703 (cryptophycin 52) in human tumor cell lines
22. Absence of HeLa cell contamination in 169 cell lines derived from human tumors
23. Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological and growth properties
24. L-Dopa decarboxylase activity (DDC): A distinguishing biomarker for the growth of small cell lung cancer (SCCL) in tissue culture
25. Effects of dibutyral cyclic adenosine 3',5'-monophosphate on the growth of cultured human small cell lung carcinoma and the specific cellular activity of L-dopa decarboxylase
26. Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination
27. Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan, antitumor activity
28. Cancer Statistics, 1998
29. Clinical highlights frolh the National Cancer Data Base: 1996
30. Randomized trials in stages I and II non-small cell lung cancer
31. Chemotherapy of advanced non-small cell lung cancer
32. Chemotherapy of small cell lung cancer
33. A randomized study of etoposide and carboplatin with or without paclitaxel in the treatment of small cell lung cancer
34. Adenocarcinoma of the colon and rectum
35. Ovarian cancer
36. European-Canadian randomized trial of taxol in relapsed ovarian cancer: High vs low dose and long vs short infusion